Retatrutide: Triple-Agonist Research Overview

Retatrutide (LY3437943) is one of the most discussed compounds in current metabolic peptide research, largely because of its triple-agonist mechanism.

What Makes It a Triple Agonist

Unlike single-target GLP-1 receptor agonists, Retatrutide is studied for activity across three receptor pathways at once: GLP-1, GIP, and glucagon. Engaging all three simultaneously is the focus of ongoing research into how combined pathway activation compares to single- or dual-agonist approaches in metabolic studies.

Why It's a Compound of Research Interest

Published trial data has generated significant interest in the compound as a comparator in studies of energy metabolism and weight-regulation biology. Its multi-receptor profile makes it a useful reference point for researchers studying how these three pathways interact.

What the Published Phase 2 Trial Reported

A Phase 2 trial of Retatrutide was published in the New England Journal of Medicine (Jastreboff et al., 2023). As with any published clinical research, the trial recorded adverse events observed in the study population. For researchers reviewing the literature, the reported findings included:

• Gastrointestinal events (nausea, diarrhea, vomiting, constipation) were the most frequently reported adverse events, generally dose-related and mostly mild to moderate.

• A modest, dose-dependent increase in heart rate was observed, peaking around week 24 before declining.

• Cutaneous hyperesthesia (skin sensitivity) was reported in 7% of participants receiving Retatrutide, versus 1% on placebo — none of these cases were severe or led to discontinuation.

• Serious adverse events were uncommon across all groups; no serious gastrointestinal events, clinically significant hypoglycemia, or thyroid-related findings were reported in the trial.

This summary reflects what was reported in the published trial literature and is provided for research and educational reference only — see the full study for methodology and complete results.

Handling and Documentation

As a lyophilized peptide, Retatrutide is typically stored cold and reconstituted with bacteriostatic water immediately prior to use in a research setting. Every batch supplied by Peptiq Wellness includes a Certificate of Analysis confirming identity and purity via third-party testing.